See more : COSMOS Pharmaceutical Corporation (3349.T) Income Statement Analysis – Financial Results
Complete financial analysis of Intersect ENT, Inc. (XENT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intersect ENT, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Tenaz Energy Corp. (TNZ.TO) Income Statement Analysis – Financial Results
- Vow ASA (VOW.OL) Income Statement Analysis – Financial Results
- Admiral Group plc (ADM.L) Income Statement Analysis – Financial Results
- Forbion European Acquisition Corp. (FRBNW) Income Statement Analysis – Financial Results
- Endymed Ltd (ENDY.TA) Income Statement Analysis – Financial Results
Intersect ENT, Inc. (XENT)
About Intersect ENT, Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.75M | 80.55M | 109.14M | 108.47M | 96.30M | 78.71M | 61.59M | 38.59M | 17.93M | 5.86M |
| Cost of Revenue | 30.01M | 30.31M | 21.77M | 22.61M | 15.50M | 13.00M | 12.29M | 10.22M | 8.15M | 3.84M |
| Gross Profit | 76.74M | 50.25M | 87.37M | 85.86M | 80.80M | 65.71M | 49.31M | 28.36M | 9.78M | 2.03M |
| Gross Profit Ratio | 71.89% | 62.38% | 80.05% | 79.15% | 83.91% | 83.48% | 80.05% | 73.51% | 54.55% | 34.56% |
| Research & Development | 27.94M | 19.35M | 24.28M | 19.26M | 18.36M | 18.89M | 16.61M | 10.33M | 9.52M | 9.26M |
| General & Administrative | 0.00 | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 122.07M | 98.55M | 108.48M | 91.60M | 80.05M | 72.93M | 59.64M | 36.11M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.23M | 9.25M |
| Operating Expenses | 150.01M | 117.90M | 132.76M | 110.87M | 98.41M | 91.82M | 76.25M | 46.44M | 27.75M | 18.51M |
| Cost & Expenses | 180.02M | 148.21M | 154.54M | 133.48M | 113.90M | 104.82M | 88.53M | 56.67M | 35.90M | 22.35M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 7.00K | 156.00K |
| Interest Expense | 6.44M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 409.00K | 117.00K | 36.00K |
| Depreciation & Amortization | 4.81M | 2.84M | 3.90M | 1.88M | 1.46M | 1.17M | 826.00K | 583.00K | 505.00K | 351.00K |
| EBITDA | -150.08M | -67.14M | -39.09M | -21.04M | -14.90M | -24.06M | -25.81M | -17.37M | -17.75M | -15.98M |
| EBITDA Ratio | -140.59% | -83.35% | -35.82% | -19.39% | -15.47% | -30.56% | -41.90% | -45.02% | -98.97% | -272.52% |
| Operating Income | -154.89M | -67.65M | -45.39M | -25.01M | -17.60M | -26.11M | -26.94M | -18.08M | -17.97M | -16.49M |
| Operating Income Ratio | -145.10% | -83.98% | -41.59% | -23.05% | -18.28% | -33.17% | -43.74% | -46.85% | -100.20% | -281.17% |
| Total Other Income/Expenses | -6.44M | -5.08M | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | -284.00K | -403.00K | 120.00K |
| Income Before Tax | -161.33M | -72.74M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Income Before Tax Ratio | -151.13% | -90.29% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| Income Tax Expense | -1.69M | -416.00K | 2.40M | 2.08M | 1.24M | 889.00K | 306.00K | 125.00K | -286.00K | 156.00K |
| Net Income | -159.64M | -72.32M | -42.99M | -22.92M | -16.36M | -25.22M | -26.63M | -18.36M | -18.37M | -16.37M |
| Net Income Ratio | -149.54% | -89.78% | -39.39% | -21.13% | -16.99% | -32.05% | -43.24% | -47.59% | -102.44% | -279.12% |
| EPS | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| EPS Diluted | -4.80 | -2.22 | -1.37 | -0.76 | -0.56 | -0.89 | -1.02 | -1.61 | -1.17 | -0.94 |
| Weighted Avg Shares Out | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
| Weighted Avg Shares Out (Dil) | 33.27M | 32.62M | 31.39M | 30.31M | 29.12M | 28.42M | 26.16M | 11.38M | 15.66M | 17.47M |
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Orthofix Announces Appointment of Thomas A. West to Board of Directors
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
Source: https://incomestatements.info
Category: Stock Reports